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CHAPTER 1 
INTRODUCTION 
 The following study is a randomized clinical trial designed to examine the 
effects of a computer-delivered form of motivational interviewing on medication 
adherence in individuals suffering from schizophrenia.  First, however, I will 
review the history and background of this disorder, the importance of medication 
in its treatment, and ways that treatment adherence have and can be addressed. 
Schizophrenia in society 
 Schizophrenic disorders are devastating for most people who are afflicted, 
and very costly for family and society.  The onset of a schizophrenic disorder 
generally occurs in the late teens to mid twenties, with some significant 
symptoms typically showing in early childhood.  If inadequately treated, a person 
with a schizophrenic disorder is likely to experience a chronic course of the 
illness resulting in severe functional impairment in many major life domains 
(Fenton & McGlashan, 1992; Hollis, 2000; McClellan, McCurry, Speltz, & Jones, 
2002; Robinson, Woerner, Alvir, et al., 1999).  Untreated persons often become 
unproductive members of society, dependent on family and public health as well 
as mental health resources (with overall annual nation-wide direct costs 
estimated at $62.7 billion) (Wu, et al., 2005). 
 This introduction will briefly examine the history of the classification of the 
disorder itself, its course, and some of the major theories of causation.  
Subsequent sections will review treatment approaches and the key issue of 
adherence to treatment.  
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History 
 Hindu elders wrote descriptions matching those of schizophrenia in the 
Ayur-veda over 3400 years ago.  A systematic review of Greek and Roman 
literature from the 5th century B.C. through the 2nd century A.D. reveals that the 
peoples of these civilizations recognized a number of psychological and even 
psychotic symptoms, even though there does not seem to be evidence that a 
syndrome matching the criteria for modern-day schizophrenia was delineated 
(Evans, McGrath & Milns, 2003).  
 The notion that mental illness possesses a genetic or hereditary 
component is more recent.  Battie (1758) saw that his patients had lunatic 
ancestors and Esquirol (1838) asserted that “heredity is the commonest cause of 
insanity” (Shorter, 1997).  By the time Kraepelin adopted Morel’s (1857) theory of 
degeneration for the fourth edition of his textbook, the term dementia praecox 
was steadily evolving into the concept of schizophrenia that we know today (Ban, 
2004).  This new term was coined by Bleuler, who characterized the syndrome 
by placing emphasis on four A’s: loose Associations, inappropriate Affect, 
Ambivalence, and Autism.  These four symptoms dominated the diagnostic 
criteria until Schneider (1957) postulated the first-rank symptoms (FRS) of 
audible thoughts, voices arguing/talking/commenting, somatic passivity 
experiences, thought withdrawal/broadcasting, delusional perceptions and 
experiences of mad volition, affect and impulse.  Mellor (1982) later found that 
FRS are not exclusive to schizophrenia. 
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 While there have been other influential classification parameters 
suggested for schizophrenia (e.g., Kleist, 1960; Leonhard, 1957), it is interesting 
to note that none of them are a major part of today’s DSM-IV criteria.  Although 
Schneider’s FRS are present to some degree in the diagnostic criteria of the ICD-
10, the DSM-IV focuses predominantly on patient’s experiencing hallucinations, 
delusions, disorganized behavior and speech, and the negative symptoms of 
avolition, alogia and affective flattening (Andreasen, 1983). 
Course  
Schizophrenia has been described as following a relatively predictable 
four-phase course.  In the first or pre-morbid phase, subtle cognitive and social 
difficulties begin to surface.  This is followed by a prodromal phase.  This second 
phase is characterized by a gradual emergence of “subtle psychotic-like 
symptoms, social withdrawal and functional decline.”  The third, or psychotic 
phase often includes florid hallucinations or delusions, while the transitional (also 
called “recovery”) phase marks the return to prior levels of functioning (although 
individuals are now more prone to relapse).  Finally, there is a stable or residual 
phase that is free from the psychotic aspects of the disorder but includes 
persistent deficits in both cognitive and social functioning (Keshavan, 2005). 
Conceptual models of causation 
A. Environmental Factors  
 It is clear that the development of schizophrenia is not solely based on 
genetic inheritance; for example, concordance for monozygotic twins is 35-50% 
rather than 100%.  One of the most enduring conceptualizations of the etiological 
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development of schizophrenia is what has come to be called the diathesis-stress 
model, which began with Paul Meehl’s landmark paper suggesting that the 
expression of schizophrenia is a function of a congenital predisposition (of 
varying strength) and environmental factors such as positive or negative “social 
reinforcement regimes,” with certain minimal levels of each being necessary for 
the disorder to manifest (Meehl, 1962).  He further postulated that other 
inheritable factors such as resistance to stress and physical vigor could be 
protective.  This idea was greatly expanded over a decade later by Zubin and 
Spring, who focused predominantly on the vulnerability aspect of the disorder 
(Zubin & Spring, 1977).  Although their model is far too complex to recreate in 
detail, it is important to note that there was a great deal of emphasis placed on 
not only environmental contingencies, but on coping strategies as well.  
Individuals were seen as having a genetic vulnerability to schizophrenia that was 
impacted by environmental forces, social-psychological experiences, and other 
genetic predispositions that may leave them more or less susceptible to stress, 
as well as protective factors such as social support and personal coping 
strategies and skills.   
Recent studies have supported the diathesis-stress model.  For example, 
Howes et al. point out that even though schizophrenia is heritable, it is not 
caused by the inheritance of a single gene, just as medical disorders such as 
coronary artery disease and diabetes are not the result of an identified single 
gene (Howes, McDonald, Cannon, Arseneault, Boydell and Murray, 2004).  
There are at least two genes that have been implicated; neuregulin for 
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neurodevelopmental problems (Stefansson, Steinthorsdottir, Thorgeirsson, 
Gulcher and Stefansson, 2004) and COMT (catechol-O-methyltransferase) for 
problems with dopamine regulation (Shifman, Bronstein, Pisante-Shalom, Lev-
Lehman, Weizman, et al., 2002).  Furthermore, many environmental factors 
continue to impact the likelihood that an individual will develop a schizophrenia-
spectrum disorder, including obstetric complications, stress, drug use, 
immigration, season of birth, head injury, and viral infection (for a complete 
review see, Austin, 2005). 
B. Biological Factors  
Recent conceptual models seek to explain the underlying brain 
mechanisms responsible for schizophrenia, and focus on very specific etiological 
sequale.  The early developmental model posits perinatal abnormalities in brain 
development as the mediating factor for problems in brain functioning in early 
adulthood (Murray & Lewis, 1987; Weinberger, 1987).  There are data that 
support this theory, in that there is a higher rate of birth complications, minor 
physical defects, behavioral problems, and neurological soft signs in children 
who later develop schizophrenia, but only a small percentage of those who 
exhibit these early difficulties actually develop schizophrenia (Keshavan, 2005). 
 Because schizophrenia develops in late adolescence/early adulthood, 
another theory postulates that the disease is the result of normal developmental 
processes gone awry.  Specifically, during this period there is normally a 
“pruning” of surplus synapses that, if excessive, could lead to a reduction of 
synapses that may lead to the onset of the disorder (Feinberg, 1982; Feinberg, 
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1990; Keshavan, et al., 1994).  Others (e.g., Lieberman et al., 2001) have 
observed that many patients deteriorate during the first few years after the onset 
of the illness, which suggests that a degenerative process may be at work.  
The pathophysiological models described above need not be mutually 
exclusive and may even occur in a sequential manner.  As stated by Lieberman, 
“…etiologic and pathogenic factors occurring long before the formal onset of the 
illness (probably in gestation) disrupt the course of normal neural development, 
resulting in subtle alteration of specific neurons and circuits, which confer 
vulnerability and may ultimately lead to malfunction”, (Lieberman et al., 2001).  
This view is shared by others (e.g., Bloom 1993; Lewis & Lieberman 2000; 
Murray & Lewis 1987; Weinberger 1987).  This may be compounded or facilitated 
by environmental factors (see earlier section), as illicit drug use and stress have 
been identified as having a contributory impact on the disorder.  
Brain changes: structural and chemical. 
There is substantial evidence that persons diagnosed with schizophrenia 
show characteristic differences in brain structure.  Specifically, increased lateral 
ventricle, reduced overall brain volume, reduced bilateral temporal lobe (Lawrie & 
Abukmeil, 1998), reduced size of the corpus callosum (Woodruff, McManus & 
David, 1995) and reduced hippocampus and amygdala-hippocampal complex 
sizes have all been reported.  More recently, Wright and colleagues confirmed 
association with increased ventricle volume and reduced overall cerebral volume 
as well as increased basal ganglia structures and bilateral medial temporal lobes 
(Wright, et al., 2000).  
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There is also evidence of chemical differences in the brains of individuals 
suffering from schizophrenic disorders.  In a comprehensive historical review of 
factors leading to what is now known as “the dopamine hypothesis,” Baumeister 
(2002) suggests that the discovery of reserpine, a drug derived from a sub-
Himalayan shrub and used originally as a psychiatric sedative, was the starting 
point for this research.  Named as a “tranquilizer” in 1953, it later became one of 
the first drugs included in neuroleptics, or drugs with extrapyramidal side effects 
(Bein, 1970; Deniker, 1983).  During this same time, serotonin was also being 
studied. Its connection to mental disorders was discovered by Gaddum, who 
observed that it antagonized LSD and determined that it therefore plays a role in 
maintaining sanity, and also by Woolley and Shaw, who noted that a lack of 
serotonin, or administration of serotonin antagonists, produces “mental 
aberrations” similar to those found in schizophrenic individuals (Gaddum, 1954; 
Woolley & Shaw, 1954).  
 While the previous research is important for the current understanding of 
the neurotransmitters involved in schizophrenia, research into the mechanisms of 
action for stimulants is most responsible for the formation of the dopamine 
hypothesis.  Jacques van Rossum, studying the action of amphetamines, found 
that they activated dopaminergic receptors and that these receptors are 
responsible for the psychomotor effects of stimulants (Rossum, 1963, 1964).  
Combined with the fact that extrapyramidal motor disturbances were known to be 
mediated by dopaminergic mechanisms and neuroleptics produce these 
disturbances, van Rossum concluded, “When the hypothesis of dopamine 
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blockade by neuroleptic agents can be further substantiated it may have fargoing 
consequences for the pathophysiology of schizophrenia.  Overstimulation of 
dopamine receptors could then be part of the aetiology.  Obviously, such an 
overstimulation might be caused by overproduction of dopamine, production of 
substances with dopamine actions (methoxy derivatives), abnormal susceptibility 
of the receptors, etc.” (Rossum, 1966, 115-126). 
 The importance of the previous section cannot be overstated, as it has a 
direct relevance to the drugs used to treat schizophrenia today.   Even though it 
clearly does not tell the entire story of the neurological underpinnings of 
schizophrenia, it has helped to guide research on pharmacological interventions.  
To date, these are the most effective means available for treating schizophrenic 
disorders and there is some evidence that continuous medication is required to 
avoid relapse (Kane, 1996); multiple relapses can result in a progressive 
deterioration of mental functioning in some patients and leave them unable to 
regain their previous level of functioning (Johnson, 1983). 
Pharmacological interventions 
 There are a number of medications currently available to individuals 
suffering from psychotic symptoms.  Antipsychotics, as previously described 
have been around for over 50 years, and although not a cure, they can assist in 
the prevention of the progression of the disease.  They have however, been 
improved upon in what are now called “atypical antipsychotics.”  This advance in 
the pharmacology of antipsychotic drugs has been important in a number of 
ways.  For example, they are better at addressing negative symptoms of the 
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disorder, they are less likely to cause extrapyramidal symptoms (Marder & 
Meibach, 1994; Tollefson, Beasley, Tamura, Tran, & Potvin, 1997; Small, Hirsch, 
Arvanitis, Miller, & Link, 1997) and tardive dyskinesia (Jeste, Lacro, Bailey, 
Rockwell, Harris, & Caleguir, 1999; Jeste, Rockwell, Harris, Lohr, & Lacro, 1999), 
and they have the potential for better outcomes in cognitive functioning than 
conventional antipsychotics (Kelleher, et al., 2002).  Surprisingly however, 
studies have suggested that atypical antipsychotics have not greatly improved 
adherence rates; for example, Dolder and colleagues reported adherence rates 
of 54.9% for atypical antipsychotics versus 50.1% for conventional antipsychotics 
(Dolder, Lacro, Dunn & Jeste, 2002).  
Adherence problems 
Rates of poor medication adherence from 11% to 80% have been 
reported in various reviews of patients with psychotic disorders in various 
settings.  While there are a number of reasons for such a large disparity (from 
patient characteristics to adverse side-effects), Van Putten attributed it to the 
subjective effect of the drugs, noting that 62% of schizophrenic inpatients who 
were dysphoric on their medications eventually refused further medication, while 
this only occurred with 11% of the patients who were syntonic (Van Putten, 
1984).  Average nonadherence increases from about 50% at 1 year after 
discharge from a psychiatric hospitalization, to 75% by the end of the second 
year after discharge (Corrigan, 1990; Fenton, Blyler, & Heissen, 1997; Weiden et 
al., 1991).  
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More recent reviews have been more specific in their reports of non-
adherence, looking specifically at non-adherence to both attending appointments 
and taking prescribed medications (Nose, Barbui & Tansella, 2003).  Using data 
from 103 studies, Nose et al. suggest that approximately 24% of individuals 
studied are non-adherent to keeping scheduled appointments while 
approximately 30% are non-adherent to medications.  Given the growing 
emphasis on early intervention and the increasing evidence that early treatment 
with antipsychotic drugs may improve overall outcome in schizophrenia 
(McGlashan, 1998), ensuring medication adherence is particularly important 
when treating patients with a schizophrenic illness.  
 Several factors account for non-adherence to medication (Fenton, Blyler, 
& Heinssen, 1997); these factors may be classified as patient related (illness 
severity, lack of insight, and concomitant substance abuse), medication related 
(extrapyramidal and other side effects, unwieldy medication regime), treatment 
provider related (inadequate therapeutic alliance) and support system related 
factors (poor family support or supervision, financial or other barriers). Poor 
medication adherence early during treatment, inadequate discharge planning and 
immediate post-discharge care also predict poor adherence over the subsequent 
course of the illness (Lacro, Dunn, Dolder, Leckband, & Jeste, 2002). Impaired 
executive cognitive functions also predict a higher likelihood of medication 
discontinuation in first episode psychoses (Robinson et al., 2002).  Finally, Nose 
and colleagues (2003) specifically identified many of the previously mentioned 
factors (lack of insight, substance abuse) as well as adding factors such as 
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positive symptoms, younger age, male gender, unemployment and low social 
functioning.  
Interventions to increase adherence 
 Several intervention techniques have been developed to address 
medication non-adherence.  Three of these have received the most attention in 
the literature: psychoeducation, behavioral training, and compliance therapy.  
Psychoeducational methods involve helping individuals to understand 
more about their illness and medications, (e.g., the positive effects of taking 
medications, and the negative consequences of not taking medications) so that 
they might be better able to participate in the decision making process involved in 
their treatment (Gray, Wykes & Gournay, 2002) and has been one of the most 
widely researched areas for intervention.  Individual medication regimens are 
carefully reviewed in order to insure that they are completely understood by the 
patient and this can be done in either a group or individual format.  
Streicker and colleagues (Streicker, Amdur & Dincin, 1986) designed a 
study that consisted of two parts.  First, they conducted a six-session didactic 
presentation that explained the biochemical theory of schizophrenia, reviewed 
the major psychiatric medications, and stressed the risks involved with illicit 
substance use.  The second part consisted of a 4-week period of weekly 
discussions aimed at the importance of compliance, its long-term benefits, and 
communication with the treating physician.  Patients were assessed at baseline 
and immediately post-intervention, as well as at a 35-week follow-up.  While 
overall self-satisfaction and medication knowledge increased, there was no 
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significant between-group difference in adherence.  Another study looking at 
group psychoeducation occurring every 2 weeks over an 8-week period also 
found no increase in adherence (Smith, Birchwood & Haddrell, 1992). 
Numerous studies have also looked at the effect of individual 
psychoeducation.  One such study randomly assigned patients to one of 4 
groups: verbal information about medication, verbal and written information about 
medication, verbal information about medication and their side-effects, and 
verbal and written information about medications and their side-effects (Brown, 
Wright & Christensen, 1987).  Similar to the previously reviewed studies, there 
was an increase in patient knowledge, but no significant effect on adherence.  
Other studies have had similar results (MacPherson, Jerrom, & Hughes 1996; 
Gray, Wykes, & Gournay 2000).  Overall, studies that have evaluated 
psychoeducational approaches to improve adherence to treatment suggest that 
such approaches increase knowledge about treatment but do not affect either 
attitude or adherence behavior.  
Behavioral tailoring/training interventions (e.g., Boczkowski, Zeichner, & 
DeSanto, 1985; Cramer & Rosenheck, 1999) focus on helping patients develop 
specific cues that incorporate aspects of their daily routine or environment to 
facilitate medication adherence.  For example, patients may be encouraged to 
pair medication intake with a particular part of the daily routine, to identify a 
highly visible location for medication bottles, or to design a calendar with 
reminders that are to be removed after the administration of each dose.  
Boczkowski (1985) randomly assigned patients into behavioral tailoring, 
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psychoeducation, and control conditions.  As measured by pill count alone, 
adherence was significantly improved in the behavioral tailoring condition, but not 
in the other two conditions. However, patient and observer ratings of adherence 
did not improve.  Whether this reflects high initial adherence ratings, inaccurate 
self-report, or adjusting the number of pills turned in for counting (in order to 
appear more adherent) is unclear.  
 Cognitive-behavioral interventions have also been applied to the problem 
of medication adherence.  Lecompte and Pelc (1996) examined five different 
approaches to facilitating medication adherence: psychoeducation, correcting 
false beliefs about medications, engaging the patient, identifying prodromal 
symptoms/developing coping strategies and behavioral interventions aimed at 
reinforcing adherent behavior.  The patients receiving the Cognitive-behavioral 
interventions spent significantly less time in the hospital than the control group.  
Whether this was due to improved coping skills or increased medication 
adherence is unclear. 
 In a precursor study of what would eventually become compliance 
therapy, Hayward & Chan (1995) piloted an intervention based on the principles 
of motivational interviewing, designed to improve medication adherence.  
Although the effects did not reach statistical significance, the individuals receiving 
the intervention showed improvements in their attitudes towards medications and 
their insight into their illness.  The authors believed that the small sample size of 
their treatment group contributed to the lack of significant findings, and were 
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impressed enough with their results to further adapt this intervention for future 
use.  The result of this adaptation is discussed below. 
Compliance Therapy (Kemp at al., 1996) is based in part on the principles 
of Motivational Interviewing (Miller & Rollnick, 1991).  Compliance Therapy 
involves a 4- to 6-session intervention using motivational techniques along with 
psychoeducation and cognitive behavioral techniques (complete details are 
available in the published manual, Kemp, Hayward & David, 1997).  The goal is 
to provide information about the benefits and side effects of medications; to 
highlight discrepancies between patients’ actions and beliefs, provide positive 
reinforcement for adaptive behaviors; to emphasize the value of staying well; and 
to encourage self-efficacy with respect to taking medications.  The evidence for 
compliance therapy is mixed, with Kemp and colleagues showing a positive 
effect on adherence (Kemp et al, 1996; Kemp, Kirov, Everitt, Hayward, & David, 
1998) while replications by other research groups show no significant effects 
(Gray, et al, 2006, Byerly et al., 2005, O’Donnell et. al., 2003).  
Interestingly, a recent comprehensive review of compliance therapy for the 
treatment of schizophrenia (McIntosh, Conlon, Lawrie, & Stanfield, 2007) did not 
include work by Kemp and colleagues because participants in these studies 
included individuals with “primary affective disorder”.  Even after widening the 
inclusion criteria to include studies wherein as few as 80% of participating 
individuals had to be diagnosed with schizophrenia or related psychotic illness, 
the work by Kemp and colleagues did not meet criteria.  The review was able to 
identify only one study that met this criterion and was based solely on the 
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components of compliance therapy, i.e., it excluded studies that added another 
intervention, or did not target medication adherence.  In that single study 
(O’Donnell, 2003), there was no significant effect of compliance therapy on 
medication adherence.  
Despite some positive findings, then, Compliance Therapy appears to be 
of questionable applicability to treatment adherence among persons with 
schizophrenia. First, studies finding positive effects have included significant 
proportions of persons whose primary diagnosis was not schizophrenia. Second, 
the positive findings from the intervention’s originators have not yet been 
successfully replicated by other research groups.  
Overall, efforts to facilitate medication and other treatment adherence 
among persons with schizophrenia have not yielded a clearly supported 
approach. Psychoeducational approaches lead to increased knowledge about 
anti-psychotic medications but not to increased medication adherence.  
Behavioral training approaches seem to have some impact on adherence but 
have ultimately been inconclusive.  They are also very costly and time 
consuming, and dissemination may be difficult to achieve.  Research on cognitive 
approaches is limited and has not directly impacted adherence, although there is 
some evidence that it may have a positive impact on reducing hospitalizations.  
Compliance Therapy has produced some promising results but has not been 
reliably replicated.  There is therefore a clear need to examine other possible 
approaches to treatment adherence in schizophrenia.  It is also important to look 
seriously at the difficulty of disseminating potentially efficacious treatments. 
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Motivational interviewing: A Potential New Direction 
 Motivational interviewing (MI) is a brief, client-centered, yet directive 
method of facilitating health behavior change among persons who are not initially 
ready to change. It has been proven effective in addressing treatment adherence 
as well as behavioral change (Rubak, et al., 2005; Burke et al., 2003).  
Furthermore, MI has already shown efficacy with individuals suffering from 
schizophrenia.  Steinberg et al. (2004) found that participants with schizophrenia 
receiving just one session of MI were significantly more likely to (a) contact a 
treatment provider regarding their tobacco use, and (b) attend their first 
scheduled session, when compared to participants given standard 
psychoeducational counseling or advice only.  In a study designed to address 
comorbidity of substance abuse and schizophrenia, Barrowclough and 
colleagues combined MI, cognitive behavioral therapy, and a family intervention 
conducted over a 9-month period and found a significant improvement in overall 
functioning (Barrowclough, et al., 2001).  The MI aspect of the intervention was 
the initial phase of treatment, designed to engage individuals who may be 
ambivalent about their drug use or treatment regimen.  In other studies as well, 
MI has been proven particularly effective in encouraging individuals to take 
advantage of treatment options open to them, rather than necessarily being the 
primary treatment itself (Burke et al., 2003). 
Although an effective method of bringing about behavior change, MI was 
empirically derived and there has been a dearth of research into the underlying 
theory that may explain the reasons for its success.  Self-determination theory 
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(SDT; Deci & Ryan, 1985, 2000, 2002) has been recently posited as an 
explanatory theory that integrates well with motivational interviewing, providing 
finer and more explicit definitions of the motivational constructs that MI 
specifically targets (Markland, Ryan, Tobin & Rollnick, 2005; Vansteenkiste & 
Sheldon, 2006).  Specifically, SDT suggests that behavior change takes place 
when an individual’s needs are met in an as autonomous manner as possible. 
Theorists have thus suggested that MI may in part work through highlighting this 
autonomy by supporting the individuals’ self-efficacy while helping them to 
reconcile the discrepancies that have kept them from doing so previously. 
 MI may thus be worth testing for its ability to facilitate medication and 
therapy adherence among persons with schizophrenia. However, as noted 
above, compliance therapy is in part based on the principles of MI and has not 
performed well in replication studies.  A possible explanation for this finding lies 
in studies of moderators of the efficacy of MI, which together suggest that 
although MI is quite efficacious with persons who are not motivated to change, it 
may be ineffective or even counter-productive with persons who are already 
motivated to change.  For example, Rohsenow and colleagues found that 
patients with higher levels of motivation prior to treatment reported less cocaine 
use and less severe alcohol problems during the following year if they did not 
receive motivational treatment (Rohsenow, Monti, Martin, et al., 2004).  Similarly, 
Stotts et al. reported that MI treatment appeared to have a detrimental effect on 
individuals with high initial motivation (Stotts, Schmitz, Rhoades, & Grabowski 
2001).  Such findings suggest that, despite the weak evidence in favor of 
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compliance therapy (which includes a motivational component), motivational 
interviewing approaches may yet be helpful with this population if baseline 
motivation to change is taken into account. 
Computer-Based Approaches: A Potential Solution for Dissemination Problems 
Computer-based interventions have the potential to reach a large number 
of individuals at a substantially lower cost, both in terms of monetary expenditure 
as well as hours of time, training, and supervision usually required by many 
therapeutic interventions.  These advantages give computer-based approaches 
great potential in terms of population impact, which can be described roughly as 
the product of an intervention’s effect size, the percent of eligible persons in the 
community who experience that intervention, and the percent decrement in effect 
size when that intervention is replicated in the community (Smeeth & Ebrahim, 
2000).  
Given the ability of computer-based approaches to potentially impact a 
substantially larger number of individuals than would otherwise be possible, 
many researchers are beginning to examine this paradigm in a number of 
different areas.  For example, computerized cognitive behavioral therapy has 
been found to result in clinically significant improvements in self-reports of 
anxiety and depression (Cavanagh, et al., 2006).  In a study of MI-based 
computer-only feedback, greater reductions in drinking behavior among heavy-
drinking college students were evident among computer-based feedback 
intervention participants relative to controls (Neighbors, Larimer and Lewis, 
2004).  Kiene and Barta (2006) used motivational interviewing techniques in a 
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study that looked at computer-delivered HIV/AIDS risk-reduction information.  
Participants displayed greater condom-related knowledge at a 4-week follow-up, 
as well as a significant increase in self-reported condom use.  A computer-based 
motivational interviewing intervention designed to reduce perinatal drug use led 
to decreases in drug use as measured at a 4-month follow-up (Ondersma, Svikis, 
& Schuster, 2007).  Finally, computer-based paradigms have been used for more 
than just therapeutic intervention.  In a study of geriatric individuals, interactive 
computer programs were found to be effective in therapy, recreation and 
educational domains (McConatha, McConatha, Deaner and Dermigny, 1995).  
Importantly, computer-based interventions have proven remarkably easy 
to use, even for persons with low reading or computer literacy (Ondersma, 
Chase, Svikis & Schuster, 2005).  The clear, self-paced, visual and aural 
presentation of these interventions may be ideal for persons with schizophrenia, 
who may appreciate having the ability to set their own pace, as well as to 
experience different media while doing so.  Certainly, some persons with 
schizophrenia may have difficulty with a computer presentation.  However, the 
potential is clear; the actual proportion of persons with schizophrenia who can 
use computer-based approaches is an important empirical question. 
Summary 
Schizophrenia is a devastating illness with far ranging effects on both the 
individual and society.  Relatively effective treatments for schizophrenia are 
available, but many patients do not adhere to their treatment regimens, resulting 
in relapses and increased severity and duration of illness.  Also, dissemination of 
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these treatments can pose problems for many service providers.  Interventions 
designed to address this adherence problem have shown mixed results, perhaps 
in part because they have (a) focused too strongly on educational approaches; 
(b) collapsed across baseline motivation to change, and (c) been difficult to 
disseminate. This study will therefore examine a tailored, computer-based 
motivational approach to adherence in schizophrenia. This approach will focus 
much more strongly on motivation than on education and knowledge, will be 
tailored to each individual patient’s motivation to adhere to their medication 
regimen, and—if successful—will be far more replicable than previous adherence 
interventions. 
Objectives and Hypotheses:  
The main objective of the proposed study is to evaluate the feasibility, 
acceptability and potential efficacy of a computer-based motivational intervention 
designed to facilitate adherence to antipsychotic medication with individuals 
diagnosed with schizophrenia.  
Primary Hypotheses:  
It is expected that the computer-delivered motivational intervention will 
demonstrate good feasibility and acceptability with this population. It is also 
predicted that, H1: patients randomly assigned to a computer-based motivational 
adherence intervention show higher rates of adherence to antipsychotic 
medication at follow-up, compared to patients assigned to a treatment-as-usual 
control condition.  
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Secondary Hypotheses:  
H2: Patients receiving computer-delivered motivational interviewing will 
show greater improvement at time 2 compared to patients in the control condition 
on the following variables: quality of life (community functioning, social relations, 
occupational functioning, and daily activities) and global functioning. H2a: these 
differences will be mediated by medication adherence.  
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Chapter 2 
METHOD 
Participants 
 Participants were individuals attending the University Psychiatric Center’s 
Services for the Treatment of Early-onset Psychosis (STEP) program and the 
schizophrenia clinic at the Arab-American Chaldean Council in Detroit, MI.  
Participants were all currently in treatment and were referred to the study by their 
psychiatrist, therapist, or social worker.  A total of 51 participants were recruited 
to participate in this study.  Participants ranged in age from 18 to 52.  Persons of 
minority race and ethnicity make up approximately 85% of patients in these 
clinics; most are low-income and the recipients of public assistance, although a 
substantial minority (approximately 25%) have private medical insurance.  All 
participants provided written informed consent.  The Wayne State University 
Institutional Review Board approved all procedures used in this study. 
Inclusion/exclusion criteria  
All individuals enrolled in the clinics who are currently on medication for 
psychotic symptoms were eligible.  Exclusion criteria included a current 
significant medical illness temporally related to psychosis.  Due to the nature of 
psychotic illnesses, the diagnostic process can be elaborate, comprehensive and 
ongoing.  The clinical team (Director of clinical programs, intake coordinators, 
trained research coordinators, clinical psychologists and psychiatrists) makes the 
initial diagnosis with all available information and this diagnosis rarely changes 
without additional information.  Length of stay in this program is dictated by the 
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patient’s stability (direct observations by clinical staff, self-report, as well as 
reports from involved significant others).  
Procedure 
 Patients were told of the study, and their freedom to decline participation, 
by medical staff from the clinic.  Participants were approached while in the 
waiting area, and if interested were directed to the researcher.  The study was 
then briefly described for all interested clinic patients; those who remained 
interested were screened for eligibility.  Eligibility requirements included a short, 
5-question post consent form (Appendix 1) designed to ensure understanding of 
the consent process and the participant’s rights, as well as the Mini-Mental 
Status Exam.  Those eligible received full informed consent dialogue; those who 
agreed to participate and signed informed consent were included in the study.  
Participants were recruited by one of the members of the clinical team and were 
either taken immediately to a separate room for the computer session or 
scheduled for a later time.  Immediately following the initial session, participants 
were scheduled for their follow-up session (4-6 weeks later).  During the initial 
session, the computer randomly assigned participants into two groups. Both 
groups completed all study-related measures, but one group received the 
computer-based intervention, while the other received only an innocuous 
attention-control session involving television show clips and music videos.  
Participants received a $10.00 gift card for each treatment/data collection 
session.  A clinic-based follow-up session ranged from 26 to 147 days, with a 
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mean interval of 44.35 days following the initial intervention/attention control 
session.   
Assessment 
Data regarding diagnosis (made by clinic staff using the SCID-IV) was 
gathered from clinic staff. All other data were collected via audio computer 
assisted self-interview technology (A-CASI; see “software” section, below).  All 
data were collected at both of the observations, and took approximately 30-45 
minutes initially and 15-20 minutes at follow-up; evaluations were kept brief to 
maximize the ability of participants to complete assessment without fatigue. 
Measures used included:   
1. Medication Adherence Rating Scale (MARS). The MARS was created as a tool 
to replace the Drug Attitude Inventory (DAI, Hogan, Awad, & Eastwood, 1983) as 
the predominant measure of medication adherence for psychoses (Thompson, 
Kulkarni, & Sergejew, 2000).  It is an easily administered, 10-item self-report 
questionnaire.  Its main asset is the ease with which it can be administered and 
interpreted.  In reliability/validity testing it was compared to the DAI and the 
Medication Adherence Questionnaire (MAQ, Morisky, Green, & Levine, 1986).  
The reliability analysis of the MARS using Cronbach’s alpha was 0.75, compared 
to 0.76 for the MAQ and 0.77 for the DAI.  The test-retest reliability assessed 
after a 2-week interval using parallel-forms Chi-square was 0.72 for the MARS, 
0.76 for the MAQ and 0.60 for the DAI.  A multi-trait-multimethod matrix was 
used to measure construct validity.  It correlated the total compliance score for 
each questionnaire with a caretaker’s estimation of compliance and blood levels 
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of medication.  The MARS significantly correlated with other measures of 
compliance, showed no relationship with the caretaker’s estimate, and was more 
strongly associated with blood levels of medication than the MAQ.   
2. Readiness rulers. Readiness rulers are a visual analogue scale rating of 
motivation and confidence regarding medication. 
3. Social Adjustment Scale (SAS; Weissman & Bothwell, 1976).  The SAS is a 54-
item measure of adaptive functioning within a variety of social contexts.  The 
SAS has a global index and subscales providing information about a number of 
role areas: work, social and leisure activities, relationships with extended family, 
marital role, parental role, family unit role, and economic role.  The SAS has fair 
internal consistency, with an alpha of .74, and good stability, with a one-month 
test-retest correlation of .74.  The SAS also has fair concurrent validity, 
correlating with the social adjustment structured interview upon which it is based, 
and good know-group validity, distinguishing a non-clinical, community sample 
from three psychiatric samples and distinguishing acutely depressed from 
recovered clients.  
Computer-based motivational intervention 
The following description is taken directly from the software developers in 
order to illustrate that the identical software was utilized as was previously 
reported by Ondersma and colleagues.  The software consists of an assessment 
section and an intervention section.  The assessment section presents questions 
one at a time using a visually attractive screen that provides only the most 
pertinent information for the participant.  Pleasant and relevant graphics 
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accompany each screen change to engage participants and help to maintain 
interest.  A three-dimensional cartoon character (in the form of a parrot) capable 
of over 50 specific animated actions (e.g., smile, wave, read a message, express 
concern, etc.) does the “talking” for the entire program (Ondersma, Chase, Svikis 
& Schuster, 2005).  This character “interacts” with each participant by guiding 
them through the presentation in a light-hearted manner, providing occasional 
humor while narrating assessment items in a relaxed, engaging setting.  
Participants listen to the narrator via headphones to insure privacy. 
The intervention was based on motivational interviewing and brief 
intervention principles, and included three components:  
1. Feedback regarding concerns about the diagnosis and medication regimen, 
as well as of the participant’s self-reported motivation (importance and 
confidence) to adhere to their medication. 
2. Pros and cons of medication adherence, as well as pros and cons of 
continuing without medication. 
3. A short video testimonial given by a Caucasian woman regarding her 
experience with her first psychotic episode and how medication was able to 
assist her in her recovery, and (in keeping with the tenets of motivational 
interviewing) the importance of her participation – and to some degree control 
– in her own medical care. 
4. A summary and query regarding the participant’s interest in beginning a 
structured adherence program; those who indicated readiness to do so 
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completed a change plan that assisted them in specifying exactly what their 
medication goals were. 
Throughout the intervention, the animated narrator helped clarify the 
participant’s answers by “reflecting” the participant’s answers back to them, in a 
non-judgmental, reworded manner that served to assure the participant that he or 
she is being understood, reflecting an atmosphere consistent with that provided 
by an actual motivational interviewing practitioner.  Participant’s second 
interaction with the computer at follow-up repeated the initial assessments as 
well as administered a 10 question assessment on their opinions about the 
intervention itself. All individuals who completed the initial assessments were 
compensated for their time as stated above.  
Control condition  
Individuals in the control condition interacted with the computer by 
watching innocuous videos and answering questions about those videos. This 
condition was designed to be indistinguishable from the intervention condition to 
anyone not watching the computer screen.  
Regardless of the condition, in all situations, a linking table was used to 
connect names to the data. This linking table was kept in a locked file cabinet, to 
which only two persons had access. 
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Chapter 3 
RESULTS 
     DATA ANALYSIS 
A. Missing data analysis 
Patterns of missing data were examined.  No missing data were found for 
either of the primary assessment measures.   
B. Data screening procedures 
Data were analyzed using SPSS version 18 (SPSS, Chicago: SPSS Inc). 
All data were initially examined for skew, kurtosis, and out of range values, 
homoscedasticity (homogeneity of variance), and univariate outliers. Histogram 
analysis revealed possible skewness, and was confirmed by a skewness factor 
larger than two times the standard error of skew. For the MARS, both baseline 
and follow-up data were moderately positively skewed and were therefore 
normalized using the logarithmic transformation. The baseline SAS data were 
substantially skewed, and therefore both baseline and follow-up SAS data were 
normalized using the logarithmic transformation. The transformations were 
successful.  Homoscedasticity was assessed using Levene’s Test within 
independent samples t-tests; results were not significant (all p’s > .10).  
C. Participant flow 
Participant flow is summarized in Figure 1. A total of 78 participants were 
approached regarding the study; 53 (67.9%) were interested and agreed to be 
screened. Two men (3.8%) were unable to pass the post consent quiz that was 
designed to ensure participant’s understanding of the informed consent process 
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and were therefore excluded.  Therefore, 51 (96.2%) met the inclusion criteria for 
participation and were randomized.  Additionally, two men who consented were 
interrupted during their baseline assessment and did not complete this portion of 
the study, leaving a total of 49 eligible for follow-up, with 24 receiving the 
intervention, and 25 receiving assessment only (control). A total of 43 (87.8%) 
completed follow-up assessment (follow-up ranged from 26 to 147 days, mean of 
44.35 days), with three men lost from each group at follow-up.   
C. Participant characteristics 
All patients were diagnosed with schizophrenia and had been prescribed 
medication. Participants were on average high school educated and 
predominantly African American.  Consistent with the epidemiological 
characteristics of schizophrenia, there were more males than females.  Sample 
characteristics are reported in Table 2. 
D. Evaluation of group equivalence at baseline and follow-up  
To assess randomization success at baseline, comparisons of 
demographic characteristics between intervention and control groups were 
conducted with t tests for normally distributed continuous characteristics (age 
and education) and chi-square tests for categorical data (gender, race).  
Independent samples t-test analyses revealed no significant differences in 
demographic characteristics between the intervention and control groups at 
baseline. Similarly, chi-square analysis revealed no significant differences in 
gender or race (Table 3).     
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Retention was good overall, with 43 out of 49 participants (87.8%) 
assessed at follow-up. Of these, 21 of 24 (87.5%) were from the intervention 
condition and 22 of 25 (88%) were from the control condition.  Data from drop-
outs were examined by comparing those who completed the follow-up (n = 43) to 
those who dropped out (n = 6) by treatment status and by baseline 
characteristics.  No significant differences were found (all p’s > .39); these 
missing data were therefore not seen as threatening the validity of the study.   
E. Evaluation of study measures 
 The range, mean, and standard deviation for all study measures are 
reported in Table 4.  The current sample scored lower on quality of life (SAS) 
than would be expected from normative data for a similar population, specifically 
in the areas of “primary relationship” and “family unit”.  Bivariate correlations 
between all study measures, including SAS subscales, are reported in Table 5. 
F.  Intervention feasibility and acceptability 
 With respect to feasibility, all participants reported that they experienced 
no problems with the program, and were able to complete the study. One 
participant stated that he preferred not to participate after being introduced to the 
program and dropped out of the study. 
Results from the assessment of software assessment/intervention 
acceptability are displayed in Table 1.  Scores for acceptability could range from 
1 – 5 on a Likert-type scale.  All items except for questions 4 and 9 were reverse-
coded such that higher scores indicated greater acceptability. Table 1 shows 
means and standard deviations for each acceptability item, demonstrating that 
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mean acceptability was over 4 for all positively-worded items.  The two 
negatively-worded items designed to pull for negative responses (“How much did 
some parts of the computer bother you?” and “How uncomfortable were you 
working with Peedy the bird?”) had mean ratings of 3.7 and 3.9, respectively.   
G. Preliminary Efficacy 
Primary Hypothesis 1:  Medication adherence.   
The main objective of the study was to evaluate the acceptability and 
initial efficacy of a computer-based motivational intervention designed to facilitate 
adherence to antipsychotic medication.  The first of two primary hypotheses was 
that patients randomly assigned to the computer-based motivational adherence 
intervention would show higher rates of adherence to antipsychotic medication at 
follow-up, compared to patients assigned to the control condition.  This was 
tested via a General Linear Model using the MARS as the repeated measures 
factor (measured at baseline and follow-up).  Patients randomly assigned to the 
computer-based motivational adherence intervention did not show higher rates of 
adherence to antipsychotic medication at follow-up, as measured by the MARS, 
compared to patients assigned to the control condition, F(1, 41) = .12, p = .73 
(Table 6).   
Primary Hypothesis 2: Quality of life  
The second primary hypothesis was that patients in the experimental 
condition would show greater improvement compared to patients in the control 
condition on a global measure of quality of life (lower scores on the SAS scale).  
This was tested via a General Linear Model where quality of life was a repeated 
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measures factor (baseline and follow-up).  Compared to patients assigned to the 
control condition, patients randomly assigned to the computer-based motivational 
adherence intervention did not show improved quality of life on the SAS scale at 
follow-up, F(1, 41) = .43, p = .52 (Table 6).    
Secondary Analyses 
Secondary analyses first focused on exploratory evaluation of potential 
moderators, to examine whether intervention effects may have been present in 
some subgroups of participants.  Four specific variables were examined as 
potential moderators: baseline MARS score and baseline SAS score (to examine 
whether treatment effects varied with level of initial adherence or quality of life), 
gender, and follow-up delay (time between baseline and follow-up).  Continuous 
variables were dichotomized using a median split and were entered into 2 X 2 
Factorial ANOVAs along with intervention condition (intervention vs. control). The 
interaction term was then examined for evidence that the effect of the 
intervention differed based on the baseline value of each of the four variables 
being examined.  When the moderator was gender and follow-up delay, the 
dependent variable used was the change score of SAS and MARS which was 
derived by subtracting the baseline value from the follow-up score.  The 
dependent variable was the time two value when the moderator being considered 
was itself at time one, (i.e., baseline MARS scores as a moderator of MARS 
outcomes and baseline SAS scores as moderator of SAS outcomes).  As seen in 
Table 7, these analyses did not provide any evidence of moderation of 
intervention effects.        
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   Secondary analyses next focused on examination of change in medication 
adherence and quality of life overall (i.e., regardless of intervention condition), 
and predictors of that change. As seen in Figure 2, the sample as a whole 
declined on medication adherence attitudes as measured by the MARS, and 
increased slightly on quality of life as measured by the SAS (scores slightly 
decreased).  Two separate linear regressions were run, exploring the association 
between demographic variables and adherence/quality of life as measured at 
baseline (education level, race, gender and age; entered simultaneously) with 
change score derived from each of the two primary outcomes. The overall model 
for the SAS change score (F(4, 34) = .98, p = .43)  was not significant, nor were 
any of the four individual measures.  The overall model for the MARS change 
score (F(4,34) = .64, p = .64)  was not significant, nor were any of the 4 individual 
measures. 
As noted above, importance and confidence were only measured at 
baseline for participants assigned to the intervention condition. In a separate 
multiple regression, the treatment-only variables of baseline importance and 
confidence were added to the overall model for the MARS and SAS change 
scores.  The overall model for the SAS change score was not significant (F(6,11) 
= 1.04, p = .45), nor were any individual measures.  The overall model for the 
MARS change score was also not significant (F(6,11) = 2.69, p = .074), but 
baseline importance was a significant predictor of change in medication 
adherence (standardized beta of -1.01, t = -2.79, p < .018). Specifically, 
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participants with higher importance scores at baseline were more likely to report 
attitudes reflecting worse medication adherence at follow-up.  
Finally, given the wide range in follow-up delay, we examined whether 
there was any association between follow-up duration and outcomes. 
Spearman’s Rho between follow-up duration and outcomes was not significant (r 
= .19 for follow-up MARS, p = .21, and r = -.21 for follow-up SAS, p = .18). 
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Chapter 4 
DISCUSSION 
The main objective of this study was to evaluate the feasibility, 
acceptability, and initial efficacy of a computer-based motivational intervention 
designed to facilitate adherence to antipsychotic medication among persons 
diagnosed with schizophrenia.  Such an intervention, if acceptable, feasible, and 
efficacious, could do much to mitigate the substantial negative consequences of 
non-adherence among persons with schizophrenia.  
Feasibility and acceptability must be determined first in the intervention 
development process, before fully engaging in the expensive and time-
consuming process of evaluating efficacy. The 43 participants for whom follow-up 
data were obtained in this study provided strong evidence for feasibility and 
acceptability of computer-delivered approaches with this population.  For 
example, most participants (87.8%) returned for a second session.  Ratings of 
enjoyment, interest, utility and respectfulness were high, ranging from a low of 
4.0 on a 1-5 scale (with 5 being best) for enjoyment of the bird’s voice, and a 
high of 4.7 for perceived respectfulness of the bird towards the participant.  
Further, only one of the 51 participants in this study - despite all having a 
diagnosis of schizophrenia - was unable or unwilling to complete the brief 
session with the computer. These findings are extremely important, and bode 
well for the future of computer-delivered content with this population.  There is 
evidence that computerized administration of cognitive remediation for individuals 
suffering from schizophrenia has been successful as well, adding further support 
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for utilizing computer-based strategies for this population (Cavallaro, Anselmetti, 
Poletti, Bechi, Ermoli, Cocchi et al., 2009; Kurtz, Seltzer, Shagan, Thime, & 
Wexler, 2007).       
Demonstration that a specific form of such content can be efficacious is 
thus a key next step. In this very preliminary examination of the efficacy of one 
possible approach, there was no observed effect of the intervention on either 
attitudes surrounding adherence to medication or on measures of quality of life. 
The study sample overall showed only very small changes on either outcome 
over the follow-up period (mean of 44 days), with no evidence of an effect for 
treatment condition.   
Despite the very small N, it was deemed appropriate to conduct 
preliminary examinations of whether intervention effects may have been present 
in some subgroups of participants, as such information can be valuable in 
guiding possible modifications to intervention approach.  There was no evidence 
of moderation of intervention effects by baseline values of the primary outcome 
measures, by gender, or by follow-up interval.  Although power to detect such 
effects is less than that for detecting main intervention group effects, this finding 
does suggest that genuine intervention effects were not likely to have been 
masked by subgroup effects. Of course, other (unmeasured) constructs could 
have acted as moderators of the intervention in this study, but the small overall 
changes regardless of condition suggest that this is not likely.    
Participant’s reports of their belief about the importance of taking their 
medication were associated with follow-up scores on attitudes about adherence.  
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That is, participants with higher importance scores at baseline were more likely to 
report attitudes reflecting worse medication adherence at follow-up.  This was 
interesting, as it seems at first glance contradictory; it initially appears that 
participants may have been duplicitous in their original self-assessment of 
importance.  It is possible however, that self-rated level of importance reflected 
an earnest belief on the part of participants, but added little to their ability to 
actually follow through with their desire to consistently take medication.  It is also 
possible that individuals who rate this with high levels of importance may also 
hold themselves to a higher subjective standard.  Finally, and consistent with 
SDT, it may be that one of the mechanisms that is posited to be responsible for 
behavior change - specifically that of autonomy- was not sufficiently addressed in 
this study.  Given the fact that there is little choice for these individuals with 
regard to effective treatments, it may be that further highlighting the choices that 
are available to them would be suitable target for improving efficacy. 
There are a number of possible reasons for the lack of overall intervention 
effect. These possibilities will be outlined below, along with limitations of the 
current study, implications of the findings, and possible future directions for 
research in this area.   
Lack of Treatment Effect 
A number of factors may account for the lack of treatment effect in the 
current study.  First, and perhaps most parsimoniously, it is possible that there is 
not a simple treatment that provides an efficacious way of addressing the 
difficulties facing this particular population.  As reviewed above, a number of 
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approaches have sought to assist individuals suffering from schizophrenia with 
medication adherence - with mixed success.  The challenges facing this 
population are considerable and finding an “easy fix” that will allow them to 
circumvent their daily difficulties has been elusive at best.  It may be that 
intensive, daily behavioral interventions are the only method whereby significant 
positive changes can be effected as discussed above, though even that evidence 
is not conclusive and appears to impact only certain domains, such as pill count 
(Boczkowski, 1985).  However, as the current intervention was tolerated and 
even liked by participants, computer-delivered motivational interventions may 
help to increase motivation to participate in daily behavioral interventions.  This 
bodes well for the possibility of utilizing the current intervention to focus solely on 
motivation for engaging in other more intensive interventions such as behavioral 
based treatments.  There is evidence that motivational interviewing is useful as a 
precursor to other established standard treatments (Hettema, Steele & Miller, 
2005). The savings in cost and time garnered by utilizing the computer 
administered treatment may be an ideal way of providing this precursor.  There 
are also other possibilities why the current intervention was unable to yield 
significant results. 
First, as reviewed above, there has been some evidence from other 
research that motivational interviewing can have success with individuals 
suffering from schizophrenia, but it may be that this specific intervention is not 
the optimal way of providing it.  It is also a possibility that the method of delivery 
via computer did not provide sufficient means for presenting the intervention.  
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Due to the nature of this illness, it is possible that internal stimuli make it difficult 
for participants to remain focused on the task at hand, and as a result may have 
a negative impact on their ability to adequately and accurately report their current 
feelings or state of mind.  Also, it is possible that attending to the program’s 
cartoon narrator is too distracting to allow them to switch their focus from him to 
their own internal state and back again.   
In addition, there is evidence from other literatures that, within a brief 
intervention format, there can be a dose-response relationship (e.g., Burke et al., 
2003). It may be the case that presenting a similar intervention on a more regular 
and repetitive basis would enable participants to derive more from the 
intervention than a single session can provide.  For example, brief interventions 
for smoking become progressively more efficacious as the number of repetitions 
and/or total duration increases, but only up to an approximate 4 session/30-
minute limit (Fiore, Jaen, Baker, Bailey, Benowitz, & Curry et al.,2008).  
Focusing still on the pervasive nature of schizophrenia, it is important to 
note that this sample scored worse on the SAS at baseline than would be 
expected based on normative data from a similar population.  Notably, the two 
subscales that the current population fared worst on were measures of what 
could be deemed as social support, namely, primary relationships and extended 
family.  It can be argued that interventions to improve functioning among this 
group need to focus first on social support before targeting higher levels of self-
actualization, in order to provide the foundation upon which other interventions 
might be built. 
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Another possible challenge to addressing the issue of medication 
adherence is that of adequate measurement.  Relying solely on measures of 
adherence attitudes, although an accepted method of measurement in the 
literature (Thompson, Kulkarni, & Segejew, 2000), is not sufficient to capture 
actual medication adherence.  Future studies, as was originally planned for this 
one, should include biomarkers of adherence such as presence of anti-psychotic 
medication in urine.  
Additionally, as a pilot, early stage feasibility study, the N and consequent 
lack of power may have prevented detection of small but meaningful changes in 
adherence attitudes and quality of life.  Even very small effects may have 
substantial importance given the consequences of non-adherence in this 
population, and the very inexpensive and replicable nature of computer-delivered 
approaches.  As this sample consisted entirely of individuals actively participating 
in treatment, there may have been ceiling effects as they had less room to 
improve than individuals not in treatment, making an effect harder to detect. 
Finally, this study utilized only a single follow-up point and a relatively 
short follow-up duration.  Although motivational approaches in general can 
appear to have a relatively immediate effect that dissipates over time, there is 
strong evidence that there are often enduring or even delayed effects (Hettema, 
J., Steele, J., & Miller, W.  2005).  Calendar-based  recall (otherwise known as 
Timeline Followback approaches) could also add much to overall validity of 
adherence measurement.  Sobell and colleagues found enduring effects of a 
brief motivational interviewing/cognitive behavioral approach on alcohol and drug 
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use and found enduring effects at 6 and 12 months post treatment (Sobell, Sobell 
& Agrawal, 2009).      
Limitations  
The limitations of the present study mirror many of the possible 
explanations of lack of treatment effect delineated above (e.g inadequate 
adherence measurement, small N); correcting for these may improve future 
research.  In addition, there are other limitations that may have impacted the 
ability of this study to yield positive results.  For example, the woman in the 
testimonial video represented only one ethnicity (Caucasian) and gender, while 
the majority of participants were African-American males.  Further, the cartoon 
character, although well received, was the only option for individuals to choose 
from.  It may also be that, if the resources to do so had been available, detailed 
focus groups with iterative modifications of the intervention may have yielded a 
better-targeted intervention.  Finally, insufficient funds prohibited implementing 
more accurate measuring of actual medication intake, or at least biomarkers of 
medication levels, and this is key to obtaining a clear picture of medication use 
patterns over time.  
Implications 
 The results of this study have at least two clear implications. First, it 
appears that many persons in treatment for psychotic disorders are able to utilize 
a computer-based format for assessment as well as for brief intervention. Issues 
regarding reality testing, anxiety, cognitive functioning, and others all may have 
suggested that this group would have difficulty with an animated narrator, but this 
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does not appear to have been the case. This finding opens up computer-
delivered assessment and intervention as one new potential tool available for use 
among this population.   
Second, these findings re-affirm that schizophrenia is a very complex 
disorder that impacts those who suffer from it in myriad ways, and does not lend 
itself to a simple, straightforward treatment that will have an immediate and 
enduring impact on all of those persons who undergo it.  It seems clear that basic 
essential needs for some of these individuals need to be addressed first, as well 
as examining the problem of a lack of social support, which may have played a 
significant role in the current study’s population. 
Future Directions 
This study accomplished the first goal of intervention development, 
demonstrating feasibility and acceptability. Future efficacy studies focusing on 
measures of motivation and biomarkers of adherence are necessary to 
determine the utility of the intervention.  Given sufficient time and resources the 
current study could be improved by focusing specifically on piloting an 
intervention that brings into play many of the previously mentioned shortcomings.  
This ideal intervention would involve increasing the number of intervention points 
and allowing each to be tailored based on the responses given by the participant 
on their previous computer interaction.  Shortening the duration between each 
treatment administration and having biomarkers for the detection of anti-
psychotic medication in the system of the patient would provide a more accurate 
and reliable measure of adherence.  It has also been suggested that electronic 
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monitoring in the form of MemsCAPS (pill bottles which record the times that 
patient’s open them to take their medication) would also allow for feedback for 
participants, allowing them to follow their own progress and the researcher to 
adjust the intervention for them accordingly (Byerly, Fisher, Carmody, & Rush, J. 
(2005).  Finally, giving the participants their choice of a number of possible 
characters with which to interact may further highlight their autonomy with regard 
to utilizing this particular intervention, as well as possibly enhancing their 
enjoyment of the same. 
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Appendix 1 
 
Post-Consent Quiz 
 
1.  What is the study about? 
2. Once you start, do you have to stay in the study if you don’t want to? 
3. Will you receive anything for your time and inconvenience? 
4. Will anybody besides the researchers be able to see your answers? 
5. If you have questions, is there a way for you to get in touch with someone 
from the study, to get some answers? 
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Appendix 2: 
 
The Medication Adherence Rating Scale (MARS) 
 
Please respond to the following statements by circling the answer which best 
describes your behaviour or the attitude you have held toward you medication in 
the past week. 
 
1. Do you ever forget to take your medication?  Yes/No 
2. Are you careless at times about taking your medication?  Yes/No 
3. When you feel better, do you sometimes stop taking your medicine?  
Yes/No 
4. Sometimes if you feel worse when you take the medicine, do you stop 
taking it?  Yes/No 
5. I take my medication only when I am sick.  Yes/No 
6. It is unnatural for my mind and body to be controlled by medication.  
Yes/No 
7. My thoughts are clearer on medication.  Yes/No 
8. By staying on medication, I can prevent getting sick.  Yes/No 
9. I feel weird, like a ‘zombie’, on medication.  Yes/No 
10. Medication makes me feel tired and sluggish.  Yes/No   
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Figure 1:  
Consort Diagram  
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Table 1 
Acceptability 
Acceptability Questions: N Min. Max. Mean SD 
How much did you like working with the computer? 43 2 5 4.42 .96 
How interesting was it? 43 2 5 4.19 1.03 
Was it respectful of you? 43 2 5 4.67 .84 
How much did some parts of the computer bother you? 43 1 5 3.70 1.28 
How helpful was it for you? 43 1 5 4.21 1.15 
How much did you like Peedy the bird? 43 1 5 4.47 1.08 
How much did you like his voice? 43 1 5 4.00 1.29 
How much did he help you think about your medication? 43 1 5 4.14 1.41 
Were you uncomfortable working with Peedy the bird? 43 1 5 3.91 1.44 
How clear and respectful was the researcher? 43 3 5 4.82 .53 
 
Note. Possible responses ranged from 1 to 5; all items except #4 and #9 reverse 
coded so that higher scores universally suggest better acceptability.  
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Table 2 
Sample Characteristics 
 
 
 
Variable Total (n = 49) Range 
Gender (%)   
          Male 33 (67.3%)  
          Female 16 (32.7%)  
Race (%)   
          African American 31 (63.3%)  
          Caucasian 7 (14.3%)  
          Arab American 3 (6.1%)  
          American Indian 1 (2.0%)  
          Asian  1 (2.0%)  
          More than one 4 (8.2%)  
Age  (SD) 29.87 (10.47)  18-52 
Years of education (SD) 12.80 (2.06) 8-18 
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Table 3 
Baseline Characteristics, Intervention vs. Control 
 
 
Note.  Race was collapsed into African American, Caucasian, and other. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Intervention Control t or χ2 df p 
 
Mean ± SD Mean ± SD    
Age  (years) 29.10 ± 9.69 30.56 ± 11.27 -.48 45 .64 
Education (years) 12.76 ± 1.93 12.83 ± 2.21 -.12 43 .91 
Gender   .26 1 .61 
Race*   4.33 2 .12 
  
50
 
Table 4 
Range, Mean, and Standard Deviations for all Study Measures (N = 49) 
Measure Range Mean/n (%) SD 
 Actual (possible)   
Taking Meds perfectly?  43 (87.8%)  
Importance Ruler (N = 24) 1-9 (1-10) 6.87 2.33 
Confidence Ruler (N = 23) 4-9 (1-10) 7.57 1.75 
MARS 0-9 (0-10) 3 2.38 
SAS 32-107 (12-283) 2.09 .65 
     Work Role    
               Work for Pay 1-23 (0-31) 1.49 .85 
               Housework 1-12 (0-31) 1.56 .92 
               Student 6-21 (0-33) 1.39 .67 
     Social and Leisure 15-50 (1-59) 2.42 .64 
     Extended Family 2-24 (1-40) 1.89 .84 
     Primary Relationship 14-31 (0-47) 2.67 .64 
     Parental 5-9 (0-21) 1.83 .52 
     Family Unit 1-16 (1-21) 2.29 1.30 
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Table 5 
Zero-Order Correlations Between all Study Measures and Subscales 
 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
1 MARS .14 .76** .25 -.41* -.27 X -.02 X .26 .45** X X -.19 -.38** 
2 SAS X .22 .64** -.67** -.63** X .63** X .64** .72** X X .75** -.06 
3 MARS2  X .25 -.68** -.47* X .06 X .36* .47** X X -.15 -.22 
4 SAS2   X -.72** -.49* X .04 X .58** .54** X X .43** -.30 
5 Import    X .61** X -.49 X -.56** -.54** X X -.48* .32 
6 Confid     X X -.38 X -.63** -.44* X X -.41 .05 
7 Wk/pay      X X X X X X X X X 
8 Hswk       X X .22 .32 X X .24 -.06 
9 Studen        X X X X X X X 
10 Soclei         X .59** X X .24 -.09 
11 ExtFa          X X X .29* .00 
12 PrimR           X X X X 
13 Paren            X X X 
14 Famu             X -.03 
15 Medsa              X 
 
Definitions of abbreviations from above: MARS = Medication Adherence Rating 
Scale, SAS = Social Adjustment scale.  MARS2/SAS2 = Same scales at follow-up.  
5 = Importance.  6 = Confidence.  The following are subscales of the SAS: 7 = 
Work for pay, 8 = Housework (unpaid), 9 = Student, 10 = Social and Leisure, 11 = 
Family outside the home, 12 = Primary Relationship, 13 = Parental, 14 = Family 
Unit, 15 = self report of medication adherence. 
**.  Correlation is significant at the .01 level. 
*.  Correlation is significant at the .05 level. 
a. Cannot be computed because at least one variable is constant. 
Correlations for subscales with an N of <14 were removed from the table. 
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Table 6 
Summary of Intervention Effects (N = 43) 
Outcome Variable Estimated Marginal Means df F p 
 Baseline Follow-up    
MARS*   1, 41 .12 .73 
          Intervention 3.71 3.33    
          Control 2.09 1.64    
SAS   1, 41 .43 .52 
          Intervention 2.08 2.02    
          Control 2.11 1.96    
* Significant difference at baseline between intervention and control, p = .041. Note:  Baseline 
MARS and SAS values were controlled for in analyses of group differences at follow-up. 
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Table 7 
Moderator analyses 
 
Outcome = MARS df F P 
    
Moderator:  Baseline MARS     
     Baseline MARS 1 19.16 .00 
     Intervention condition 1 2.66 .11 
     Baseline MARS x condition 1 1.17 .29 
    
Moderator:  Baseline SAS    
     Baseline SAS 1 .05 .83 
     Intervention condition 1 .12 .73 
     Baseline SAS x condition 1 .02 .89 
    
Moderator:  Gender    
     Gender 1 .08 .78 
     Intervention condition 1 .90 .35 
     Gender x condition 1 .03 .88 
    
Moderator: Follow-up Delay 
     Follow-up Delay                                           
 
1       
 
2.10 
 
.16 
     Intervention condition 1 .21 .65 
     Follow-up Delay x condition 1 .81 .38 
    
    
Outcome = SAS df F P 
    
Moderator:  Baseline MARS     
     Baseline MARS 1 .25 .62 
     Intervention condition 1 .59 .45 
     Baseline MARS x condition 1 .06 .80 
    
Moderator:  Baseline SAS    
     Baseline SAS 1 22.94 .00 
     Intervention condition 1 .12 .74 
     Baseline SAS x condition 1 .81 .37 
    
Moderator:  Gender    
     Gender 1 .61 .44 
     Intervention condition 1 2.83 .10 
     Gender x condition 1 .15 .70 
 
Moderator: Follow-up Delay 
   Follow-up Delay 
   Intervention Condition 
   Follow-up Delay x condition 
 
 
1 
1 
1 
 
5.93 
.16 
2.67 
 
.02 
.70 
.11 
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Figure 2 
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 Despite the documented efficacy of medication treatments for individuals 
suffering from schizophrenia, many individuals suffering from this disorder are 
unable or unwilling to adhere to their medication regimen.  This may be due to 
the inability of providers to differentially address the individual motivation levels of 
their patients.  The few interventions that have shown promise are both costly 
and difficult to disseminate.  The current study is a randomized controlled trial 
which utilizes motivational interviewing, delivered with an interactive computer 
based delivery system to address attitudes about adherence.  Feasibility, 
acceptability and efficacy were examined as outcomes.  While both feasibility 
and efficacy were shown to be strong indicators that this is a viable way to reach 
this population, there was no significant increase in attitudes surrounding 
adherence. 
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